Journal Article

Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095

Jeffrey T. Schouten, Amy Krambrink, Heather J. Ribaudo, Anne Kmack, Nancy Webb, Cecilia Shikuma, Daniel R. Kuritzkes and Roy M. Gulick

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 50, issue 5, pages 787-791
Published in print March 2010 | ISSN: 1058-4838
Published online March 2010 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/650539
Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious.

Clinical trials registration. NCT00013520.

Journal Article.  2214 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.